The abstract is read at the publisher; the summary is JClub's.
Nivolumab plus ipilimumab delivers long-term overall survival benefit versus chemotherapy in metastatic non-small cell lung cancer, with 7-year OS rates of 19% vs 10% (PD-L1 ≥1%) and 14% vs 4% (PD-L1 <1%).
- Why it matters: First-line options for metastatic NSCLC need durable survival gains beyond chemotherapy, especially across differing PD-L1 expression levels.
- What they did: In CheckMate 227 Part 1, adults with stage IV/recurrent NSCLC without sensitizing EGFR/ALK mutations were randomized to nivolumab plus ipilimumab, nivolumab alone, nivolumab plus chemotherapy, or chemotherapy, stratified by PD-L1 ≥1% (n=1189) or <1% (n=550), with outcomes including overall survival and safety.
- The result: At ≥91.9 months follow-up, the OS hazard ratios were 0.78 (95% CI 0.67–0.91) for PD-L1 ≥1% and 0.64 (95% CI 0.51–0.79) for PD-L1 <1%, with no new safety signals and higher 7-year ongoing response rates among responders.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.